CGS-16949A, A NEW AROMATASE INHIBITOR IN THE TREATMENT OF BREAST-CANCER - A PHASE-I STUDY

被引:19
作者
BERETTA, KR
HOEFFKEN, K
KVINNSLAND, S
TRUNET, P
CHAUDRI, HA
BHATNAGAR, AS
GOLDHIRSCH, A
CAVALLI, F
机构
[1] OSPED SAN GIOVANNI BELLINZONA, SERV ONCOL, CH-6500 BELLINZONA, SWITZERLAND
[2] UNIV CLIN ESSEN, W GERMANY TUMOR CTR, ESSEN, GERMANY
[3] REG HOSP TRONDHEIM, TRONDHEIM, NORWAY
[4] CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND
关键词
Advanced breast cancer; Aromatase inhibitor; CGS; 16949A; Phase I trial;
D O I
10.1093/oxfordjournals.annonc.a057795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Forty-six postmenopausal women with either locally advanced or metastatic breast cancer were treated with the aromatase inhibitor CGS 16949A in three different daily doses (0.3 mg, 0.6 mg and 0.9 mg total daily dose). 41 patients (89%) were pretreated by endocrine treatment for metastatic disease; 30 of these 41 were also pretreated with chemotherapy. Of the remaining 5 patients (11%) 3 were previously treated with chemotherapy alone and 2 were not pretreated. Evaluable sites of disease were: skin and soft tissue (including local recurrence) in 34, bone in 31, lung in 14 and viscera in 13 instances, respectively. 1 PR (3%) and 9 stable diseases (24%) were observed in the 37 patients assessable for response. All but two of these results were observed in the 0.9 mg group. Time to progression was 14 months for the patient showing a PR, and the median time to progression for those with stable disease was 6 months (range 6 to 23 months). Plasma estradiol and estrone levels were measured in patients receiving the daily dose of 0.6 mg (n = 4) and 0.9 mg (n = 15). The estrone levels decreased from a mean of 23.1 pg/mL (SD 17.1) to 10.5 pg/mL (SD 6.6) in the 0.6 mg-group and from 21.2 pg/mL (SD 18.9) to 9.1 pg/mL (SD 5.5) in the 0.9 mg-group within 4 days of drug administration (p < 0.0001 from baseline in both groups, with no significant difference between doses). Plasma estradiol levels decreased from 12 pg/mL (SD 12.6) to 6.0 pg/mL (SD 3.6) in the 0.6 mg-group and from 9.5 pg/mL (SD 6.5) to 6.1 pg/mL (SD 2.6) in the 0.9 mg-group (p < 0.01). The suppression of estradiol and estrone was maintained during the subsequent measurements on days 8 and 29 in the 0.9 mg group (n = 14). There was no significant change over time in cortisol levels, nor was there any significant difference between the three doses at any given time. Toxicity was mostly mild and consisted mainly of loss of appetite (7/46 = 15%), fatigue (5/46 = 11%) and nausea (4/46 = 9%) at all three dose levels.We conclude that the aromatase inhibitor CGS 16949A is well tolerated within the ranges tested and does not affect the cortisol level. Although, as observed by others, suppression of plasma estrone might be enhanced by higher doses of CGS 16949A, some antitumor effect can already be seen with 0.9 mg daily. © 1990 Kluwer Academic Publishers.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 26 条
[1]   AROMATASE IN BREAST-CANCER AND THE ROLE OF AMINOGLUTETHIMIDE AND OTHER AROMATASE INHIBITORS [J].
BRODIE, AMH ;
SANTEN, RJ .
CRC CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1986, 5 (04) :361-396
[2]   LOW-DOSE AMINOGLUTETHIMIDE WITHOUT HYDROCORTISONE FOR THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER [J].
BRUNING, PF ;
BONFRER, JMG ;
HART, AAM ;
VANDERLINDEN, E ;
DEJONGBAKKER, M ;
MOOLENAAR, AJ ;
NOOIJEN, WJ .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :369-376
[3]  
CHAKRABORTY J, 1972, BIOCHEM J, V130, pP19
[4]   INHIBITION OF ADRENAL CORTICOSTEROID SYNTHESIS BY AMINO-GLUTETHIMIDE - STUDIES OF MECHANISM OF ACTION [J].
DEXTER, RN ;
FISHMAN, LM ;
NEY, RL ;
LIDDLE, GW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1967, 27 (04) :473-+
[5]   A COMPARISON OF THE ENDOCRINE EFFECTS OF LOW-DOSE AMINOGLUTETHIMIDE WITH AND WITHOUT HYDROCORTISONE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS [J].
DOWSETT, M ;
HARRIS, AL ;
STUARTHARRIS, R ;
HILL, M ;
CANTWELL, BMJ ;
SMITH, IE ;
JEFFCOATE, SL .
BRITISH JOURNAL OF CANCER, 1985, 52 (04) :525-529
[6]  
DOWSETT M, 1989, CANCER RES, V49, P1306
[7]   EFFECTS OF AMINO-GLUTETHIMIDE ON ADRENAL FUNCTION IN MAN [J].
FISHMAN, LM ;
LIDDLE, GW ;
ISLAND, DP ;
FLEISCHER, N ;
KUCHEL, O .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1967, 27 (04) :481-+
[8]   EVIDENCE THAT CORTICOSTERONE IS NOT AN OBLIGATORY INTERMEDIATE IN ALDOSTERONE BIOSYNTHESIS IN THE RAT ADRENAL [J].
HAUSLER, A ;
MONNET, G ;
BORER, C ;
BHATNAGAR, AS .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 34 (1-6) :567-570
[9]   AN INVITRO METHOD TO DETERMINE THE SELECTIVE-INHIBITION OF ESTROGEN BIOSYNTHESIS BY AROMATASE INHIBITORS [J].
HAUSLER, A ;
SCHENKEL, L ;
KRAHENBUHL, C ;
MONNET, G ;
BHATNAGAR, AS .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 33 (01) :125-131
[10]  
KENNEDY BJ, 1965, CANCER, V18, P1551, DOI 10.1002/1097-0142(196512)18:12<1551::AID-CNCR2820181206>3.0.CO